


Claims

1. A compound of formula (I)



a stereochemically isomeric form thereof, an *N*-oxide form thereof, or a pharmaceutically acceptable acid or base addition salt thereof, wherein $-R^1-R^2-$ is a bivalent radical of formula

- O-CH₂-O- (a-1),
- O-CH₂-CH₂- (a-2),
- O-CH₂-CH₂-O- (a-3),
- O-CH₂-CH₂-CH₂- (a-4),
- O-CH₂-CH₂-CH₂-O- (a-5),
- O-CH₂-CH₂-CH₂-CH₂- (a-6),
- O-CH₂-CH₂-CH₂-CH₂-O- (a-7),
- O-CH₂-CH₂-CH₂-CH₂-CH₂- (a-8),

wherein in said bivalent radicals optionally one or two hydrogen atoms on the same or a different carbon atom may be replaced by C₁₋₆alkyl or hydroxy,

R^3 is hydrogen, halo, C_{1-6} alkyl or C_{1-6} alkyloxy;

20 R⁴ is hydrogen, halo, C₁₋₆alkyl; C₁₋₆alkyl substituted with cyano, or C₁₋₆alkyloxy;

C₁₋₆alkyloxy; cyano; amino or mono or di(C₁₋₆alkyl)amino;

R^5 is hydrogen or C_1 -6alkyl, and the $-OR^5$ radical is situated at the 3- or 4-position of the piperidine moiety;

L is a radical of formula

25	-Alk-R ⁶	(b-1),
	-Alk-X-R ⁷	(b-2),
	-Alk-Y-C(=O)-R ⁹	(b-3),
	-Alk-C(=O)-NH-C(=O)-R ¹¹	(b-4),
	-Alk-C(=O)-NH-SO ₂ -R ¹¹	(b-5),
30	-Alk-SO ₂ -NH-C(=O)-R ¹¹	(b-6),
	-Alk-SO ₂ -NH-SO ₂ -R ¹¹	(b-7),
	wherein each Alk is C ₁₋₁₂ alkanediyl; and	

R^6 is aminosulfonyl optionally substituted with C_{1-4} alkyl, C_{3-6} cycloalkyl or phenyl;

R^7 is C_{1-6} alkylsulfonyl;

X is NR⁸; said R⁸ being C₁₋₆alkyl;


R⁹ is C₁₋₆alkylsulfonylamino;

Y is a O, S, or NR¹⁰ wherein R¹⁰ is hydrogen or C₁₋₆alkyl; and

R¹¹ is C₁₋₆alkyl or phenyl.

5


2. A compound as claimed in claim 1 wherein the -OR⁵ radical is situated at the 3-position of the piperidine moiety having the trans configuration.
3. A compound as claimed in claim 2 wherein the absolute configuration of said piperidine moiety is (3S, 4S).
4. A compound as claimed in any of claims 1 to 3 wherein L is a radical of formula (b-1) wherein Alk is C₁₋₄alkanediyl, and R⁶ aminosulfonyl or aminosulfonyl substituted with C₁₋₄alkyl or phenyl.
- 15 5. A compound as claimed in any of claims 1 to 3 wherein L is a radical (b-5) wherein Alk is C₁₋₄alkanediyl, and R¹¹ is C₁₋₄alkyl.
6. A compound as claimed in any of claims 1 to 3 wherein L is a radical (b-7) wherein Alk is C₁₋₄alkanediyl, and R¹¹ is C₁₋₄alkyl.
- 20 7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound according to any of claims 1 to 6.
8. A process for preparing a pharmaceutical composition according to claim 7 wherein a therapeutically active amount of a compound according to any of claims 1 to 6 is intimately mixed with a pharmaceutically acceptable carrier.
- 25 9. A compound according to any of claims 1 to 6 for use as a medicine.
- 30 10. A process for preparing a compound of formula (I) wherein
 - a) an intermediate of formula (II) is reacted with an carboxylic acid derivative of formula (III) or a reactive functional derivative thereof;



35

-47-

b) an intermediate of formula (IV) is *N*-alkylated with an intermediate of formula (V), in a reaction-inert solvent and, optionally in the presence of a suitable base;



5

wherein in the above reaction schemes the radicals $-R^1-R^2-$, R^3 , R^4 , R^5 , and L are as defined in claim 1 and W is an appropriate leaving group;

10 c) or, compounds of formula (I) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (I) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

15